(VIANEWS) – The NASDAQ opens in less than four hours and Xenetic Biosciences‘s pre-market value is already 8.46% down.
The last session, NASDAQ ended with Xenetic Biosciences (XBIO) dropping 2.97% to $0.64. NASDAQ slid 0.95% to $11,425.05, following the last session’s downward trend on what was a somewhat down trend trading session.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical firm that focuses on advancing XCART, a customized chimeric receptor T cell (CART) platform technology designed to target specific patient-specific tumour neoantigens. It is involved in research and development of oncology therapies and biologic drugs. Cell-based therapies that target the B-cell receptor are developed to treat B-cell lymphomas. By partnering with pharmaceutical and biotechnology companies, it is also using PolyXen, their proprietary drug delivery platform. Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited have signed collaboration agreements. Xenetic Biosciences, Inc. has its headquarters in Framingham, Massachusetts.
Today’s last reported volume for Xenetic Biosciences is 26997, 43.86% below its average volume of 48092.
Xenetic Biosciences’s last close was $0.64, 73.37% under its 52-week high of $2.42.
The company’s growth estimates for the current quarter and the next is 20% and 15.4%, respectively.
Xenetic Biosciences’s last day, last week, and last month’s current intraday variation average was 3.03%, 4.25%, and 4.24%, respectively.
Xenetic Biosciences’s highest amplitude of average volatility was 9.20% (day), 10.43% (last week), and 10.50% (last month), respectively.
More news about Xenetic Biosciences (XBIO).